Education
About Us
Working with TipRanks
Follow Us
OmniAb (OABI)
NASDAQ:OABI
OABI Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.23 - $5.54
Previous CloseN/A
Volume80.31K
Average Volume (3M)743.27K
Market Cap
$298.01M
Enterprise Value$397.58M
Total Cash (Recent Filing)$16.36M
Total Debt (Recent Filing)$25.56M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
May 08, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.61
Shares Outstanding122,134,940
10 Day Avg. Volume1,109,491
30 Day Avg. Volume743,266
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)11.71
Price to Cash Flow (P/CF)-20.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.33
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit11.64
Enterprise Value/Ebitda-6.35
Forecast
1Y Price Target
$7.40Price Target Upside204.53% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
OmniAb News
PremiumCompany Announcements
OmniAb’s Earnings Call: Growth Amid Challenges---
Bulls Say, Bears Say
Bulls Say
Business ModelOABI is viewed as a differentiated antibody therapeutics animal platform provider enabling market-leading partner program growth and a highly scalable business model.
Partnership GrowthOmniAb experienced approximately 18% growth year over year in the number of active partners and programs.
Bears Say
Financial OutlookOABI initiated guide at $20M-$25M, coming in below the Street's $46M and analyst's $33M, raising concerns about its financial outlook.
Revenue GuidanceThe fiscal year revenue guidance of $20-25M was more conservative than expected, falling below consensus estimates.
---
Ownership Overview
32.19% Insiders
19.58% Mutual Funds
18.64% Other Institutional Investors
20.71% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OABI FAQ
What was OmniAb’s price range in the past 12 months?
OmniAb lowest stock price was $2.23 and its highest was $5.54 in the past 12 months.
What is OmniAb’s market cap?
OmniAb’s market cap is $298.01M.
When is OmniAb’s upcoming earnings report date?
OmniAb’s upcoming earnings report date is May 08, 2025 which is in 41 days.
How were OmniAb’s earnings last quarter?
OmniAb released its earnings results on Mar 18, 2025. The company reported -$0.12 earnings per share for the quarter, missing the consensus estimate of -$0.101 by -$0.019.
Is OmniAb overvalued?
According to Wall Street analysts OmniAb’s price is currently Undervalued.
Does OmniAb pay dividends?
OmniAb does not currently pay dividends.
What is OmniAb’s EPS estimate?
OmniAb’s EPS estimate is -0.16.
How many shares outstanding does OmniAb have?
OmniAb has 122,134,940 shares outstanding.
What happened to OmniAb’s price movement after its last earnings report?
OmniAb reported an EPS of -$0.12 in its last earnings report, missing expectations of -$0.101. Following the earnings report the stock price went down -20.376%.
Which hedge fund is a major shareholder of OmniAb?
Currently, no hedge funds are holding shares in OABI
---
OmniAb Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.40 (204.53% Upside)
$7.40 (204.53% Upside)
Hedge Fund Trend
Increased
By 371.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $304.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-54.04%
12-Months-Change
Fundamentals
Return on Equity
-20.60%
Trailing 12-Months
Asset Growth
-10.79%
Trailing 12-Months
Company Description
OmniAb
OmniAb (OABI) is a biotechnology company specializing in the development and commercialization of innovative therapeutic antibody discovery technologies. Operating within the pharmaceutical and biotechnology sectors, OmniAb provides drug discovery platforms that accelerate the development of biologic drugs. Their core products and services include proprietary antibody discovery platforms that leverage advanced technologies to identify and optimize therapeutic antibodies for pharmaceutical companies and academic institutions.
---
OABI Company Deck
---
OABI Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
OmniAb exhibited strong growth in active partnerships and revenue, highlighting the positive reception of their technologies and notable advancements in their pipeline. However, the decline in service revenue, impairment charges, and reduced revenue guidance for 2025 present challenges. The overall sentiment is cautiously optimistic, with a balanced view of achievements and obstacles.Read More>---
OABI Stock 12 Month Forecast
Average Price Target
$7.40
▲(204.53% Upside)
Technical Analysis
Alnylam Pharma
―
BioMarin Pharmaceutical
―
Xenon
―
Argenx Se
―
Adaptive Biotechnologies
―
Best Analysts Covering OABI
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
-6.80%
reiterated a buy rating 10 days ago
Copying Puneet Souda's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -6.80% per trade.
---